Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

SBRT Appears to be Superior to CRT for Controlling Pain Related to Spinal Metastases

October 31, 2020
By Hannah Slater
Article
Conference|American Society for Radiation Oncology Annual Meeting (ASTRO)

Stereotactic body radiotherapy may be superior to conventional palliative radiotherapy in improving the complete response rate for pain related to spinal metastases at 3- and 6-months post-radiation.

Stereotactic body radiotherapy (SBRT) may be superior to conventional palliative radiotherapy (CRT) in improving the complete response (CR) rate for pain related to spinal metastases at 3- and 6-months post-radiation, according to a randomized phase 2/3 trial presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting.1

Specifically, more than twice as many patients treated with SBRT reported an enduring, complete reduction in pain, compared to those treated with CRT.

“This is the first phase 3 randomized trial that has shown an improvement with dose escalation for painful spinal lesions,” lead author Arjun Sahgal, MD, a professor and deputy chief of radiation oncology at the Sunnybrook Health Sciences Centre of the University of Toronto, said in a press release.2 “Pain deteriorates a patient’s quality of life and nobody with advanced cancer should have to endure this kind of pain. Patients with painful spinal metastases who meet the eligibility criteria should be offered this treatment.”

In this study, patients with a de novo site of painful spinal metastases were randomized 1:1 to receive either 24Gy in 2 SBRT fractions or 20Gy in 5 CRT fractions. Patients included in the study had a target site spinal metastases (≤3 consecutive metastatically involved spinal segments) arising from a solid primary tumor causing a pain score of 2 or more using the Brief Pain Inventory (BPI), an ECOG of 0 to 2, and were not mechanically unstable per the Spinal Instability Neoplasia Score classification system.

The primary end point for the study was CR rate for pain in the treatment area at 3 months post-radiation using International Consensus Pain Response Endpoints. Key secondary end points included the 6-month pain CR rate, radiation site progression-free-survival (RSS PFS) defined as the time from randomization to local progression or death, and quality of life (QoL).

Of the 229 patients enrolled between January 2016 and September 2019, 115 were randomized to CRT and 114 to SBRT of which 4 patients in the SBRT arm were either ineligible or withdrew prior to radiation. Moreover, 38 patients, including 22 in the CRT arm and 16 in the SBRT arm, were not evaluable for the primary end point.

The median baseline worst pain score was 5 (range, 2-10) and SINS was 7 (range, 3-12) in both arms. Median follow-up time was 6.7 months.

At 3 months, 14% (16/115) in the CRT arm versus 36% (40/114) in the SBRT arm (P < .001) achieved a CR to pain. This significance was retained in multivariable analyses (P < .001) and the risk ratio (RR) was 1.33 (95% CI, 1.14-1.55) favoring SBRT.

At 6 months, 16% (18/115) in the CRT arm versus 33% (37/114) in the SBRT arm achieved a CR (P = .004), with significance again retained on multivariate analysis (P < .001); additionally, the RR was 1.24 (95% CI, 1.07-1.44) favoring SBRT.

“This was not just, ‘Oh, I feel a little bit better,’” said Sahgal, adding that patients experienced the reduction in pain without increasing the use of pain medications.

“We applied a very stringent trial design to focus on the impact of radiation,” Sahgal continued. “It was the radiation treatment that led to the improvement.”

There was no difference between the study arms in RSS PFS or overall survival (OS). The 3-month RSS PFS for CRT versus SBRT was 86% versus 92% (P = .4), and at 6 months was 69% versus 75% (P = .42), respectively. For QoL outcomes, only financial perception at 1 month significantly differed (P = .03) and favored SBRT.

Regarding safety, both treatments were found to be safe with respect to fractures and there was no radiation damage to the spinal cord observed in either cohort. There were 20 (17%) patients in the CRT arm and 12 (11%) in the SBRT arm with post-radiation vertebral compression fractures. Further, 2 (2%) patients in the CRT am and none (0%) in the SBRT arm progressed to malignant epidural spinal cord compression.

Grade 2 or more adverse events (AEs) were seen in 12% and 11% in the CRT and SBRT arms, respectively, and no Grade 5 AEs were observed.

“We saw we were getting improvements in pain, but our patients were not pain-free. With the development of SBRT, and spinal SBRT in particular, we started to wonder if we could do better. With these new research results, we think we can,” Sahgal concluded.

References:

1. Sahgal A, Myrehaug SD, Siva S, et al. CCTG SC.24/TROG 17.06: A Randomized Phase II/III Study Comparing 24Gy in 2 Stereotactic Body Radiotherapy (SBRT) Fractions Versus 20Gy in 5 Conventional Palliative Radiotherapy (CRT) Fractions for Patients with Painful Spinal Metastases. Presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting. Abstract #: LBA 2.

2. Treating spinal metastases with fewer and higher doses of radiation reduces pain more effectively [news release]. Arlington, Virginia. Published October 26, 2020. Accessed October 30, 2020. https://www.newswise.com/articles/treating-spinal-metastases-with-fewer-and-higher-doses-of-radiation-reduces-pain-more-effectively?sc=sphr&xy=10021790

Recent Videos
The Jack & Sheryl Morris Cancer Center offers “state-of-the-art” surgical suites and advanced radiation technology, says Andrew M. Evens, DO, MBA, MSc.
A study aimed to determine the variables that correlated with extravasation rates in patients receiving radiation injection therapy.
Extravasation with beta emitters may elicit more drastic adverse effects due to their higher radiation dose.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Multidisciplinary collaboration may help in minimizing the treatment burden among patients with prostate cancer, according to Curtiland Deville Jr., MD.
Focused, high-dose radiotherapy doses may prolong survival and the interval to subsequent therapy for patients with advanced prostate cancer.
Data show increasing use of proton therapy overall but widening gaps in populations who have access to this treatment, says Curtiland Deville Jr., MD.
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Related Content
Advertisement

Novel Therapy Receives FDA RMAT Designation in Localized Prostate Cancer

Novel Therapy Receives FDA RMAT Designation in Localized Prostate Cancer

Tim Cortese
May 29th 2025
Article

Full results from the phase 3 trial supporting CAN-2409 plus valacyclovir and radiation therapy in this indication will be presented at the 2025 ASCO Annual Meeting.


A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

Elucidating Noninvasive Radiosurgery Advancements in CNS Tumors

William R. Kennedy, MD
April 28th 2025
Podcast

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.


IMRT Does Not Improve Tolerability vs 3D-CRT in Advanced Rectal Cancer

IMRT Does Not Improve Tolerability vs 3D-CRT in Advanced Rectal Cancer

Tim Cortese
May 27th 2025
Article

Intensity-modulated radiotherapy increased some lower-grade toxicities vs 3D conformal radiotherapy in patients with locally advanced rectal cancer.


Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.


Navigating the Landscape of PSMA PET Imaging Agents in Prostate Cancer

Navigating the Landscape of PSMA PET Imaging Agents in Prostate Cancer

ONCOLOGY Staff
May 24th 2025
Article

Prostate-specific membrane antigen PET imaging has completely altered the landscape of prostate cancer detection and management. Read as several experts discuss the trajectory and growth of these agents.


The Radiation Oncology Perspective: Genomic vs Genetic Testing in Prostate Cancer

The Radiation Oncology Perspective: Genomic vs Genetic Testing in Prostate Cancer

ONCOLOGY Staff
May 22nd 2025
Article

Decipher Prostate, Oncotype DX, and Prolaris are 3 gene expression testing options for patients with prostate cancers. Read as experts discuss them.

Related Content
Advertisement

Novel Therapy Receives FDA RMAT Designation in Localized Prostate Cancer

Novel Therapy Receives FDA RMAT Designation in Localized Prostate Cancer

Tim Cortese
May 29th 2025
Article

Full results from the phase 3 trial supporting CAN-2409 plus valacyclovir and radiation therapy in this indication will be presented at the 2025 ASCO Annual Meeting.


A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

Elucidating Noninvasive Radiosurgery Advancements in CNS Tumors

William R. Kennedy, MD
April 28th 2025
Podcast

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.


IMRT Does Not Improve Tolerability vs 3D-CRT in Advanced Rectal Cancer

IMRT Does Not Improve Tolerability vs 3D-CRT in Advanced Rectal Cancer

Tim Cortese
May 27th 2025
Article

Intensity-modulated radiotherapy increased some lower-grade toxicities vs 3D conformal radiotherapy in patients with locally advanced rectal cancer.


Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.


Navigating the Landscape of PSMA PET Imaging Agents in Prostate Cancer

Navigating the Landscape of PSMA PET Imaging Agents in Prostate Cancer

ONCOLOGY Staff
May 24th 2025
Article

Prostate-specific membrane antigen PET imaging has completely altered the landscape of prostate cancer detection and management. Read as several experts discuss the trajectory and growth of these agents.


The Radiation Oncology Perspective: Genomic vs Genetic Testing in Prostate Cancer

The Radiation Oncology Perspective: Genomic vs Genetic Testing in Prostate Cancer

ONCOLOGY Staff
May 22nd 2025
Article

Decipher Prostate, Oncotype DX, and Prolaris are 3 gene expression testing options for patients with prostate cancers. Read as experts discuss them.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.